DA Davidson upgraded Phreesia from Neutral to Buy and set a new price target of $32.00 from $30.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2024 | $35.00 | Buy | Truist |
| 1/17/2024 | $30.00 → $32.00 | Neutral → Buy | DA Davidson |
| 1/3/2024 | $29.00 | Overweight | Barclays |
| 4/12/2023 | $37.00 | Overweight | Stephens |
| 1/4/2023 | $35.00 → $40.00 | Buy | Needham |
| 12/13/2022 | $40.00 | Neutral → Buy | Citigroup |
| 12/9/2022 | $31.00 → $34.00 | Mkt Perform → Outperform | SVB Leerink |
| 10/13/2022 | $25.00 | Neutral | DA Davidson |
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
10-Q - Phreesia, Inc. (0001412408) (Filer)
8-K - Phreesia, Inc. (0001412408) (Filer)
8-K - Phreesia, Inc. (0001412408) (Filer)
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal third quarter 2025 financial results after the close of market trading on Monday, Dec. 9, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal third quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or visit th
Phreesia, a leader in patient intake, outreach and activation, and a member of Oracle PartnerNetwork (OPN), today announced that it has achieved Oracle Validated Integration with Oracle Health Electronic Health Record (EHR) Expertise for its integration of the Phreesia platform. Phreesia gives clients a suite of tools to manage patient intake across care settings and service lines. Its logic-driven tools enable healthcare organizations to operate more efficiently and provide a high-quality patient experience at scale. Expertise is a core tenet of the Oracle PartnerNetwork (OPN) program and allows Oracle partners to highlight their capabilities in a focused area. Ultimately, Expertise is de
Phreesia will work with the NAI to shape the national conversation around data privacy and promote consumer choice and transparency As part of the company's ongoing commitment to consumer data privacy, Phreesia is pleased to announce it has joined the Network Advertising Initiative (NAI), a non–profit organization and the leading self-regulatory association dedicated to responsible data collection and use for digital advertising. As a member, Phreesia will work with the NAI to promote consumer-centric privacy practices in healthcare and take a leadership role in shaping the national conversation around data privacy. "We are excited to join the NAI, an organization that shares our dedicati
Truist initiated coverage of Phreesia with a rating of Buy and set a new price target of $35.00
DA Davidson upgraded Phreesia from Neutral to Buy and set a new price target of $32.00 from $30.00 previously
Barclays initiated coverage of Phreesia with a rating of Overweight and set a new price target of $29.00
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal third quarter 2025 financial results after the close of market trading on Monday, Dec. 9, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal third quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or visit th
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2024. "We reached another very important milestone in Phreesia's evolution by crossing over to positive Free cash flow1 in the fiscal second quarter of 2025," said CEO and Co-Founder Chaim Indig. "We believe this milestone marks the start of a new era for Phreesia in which we are able to deploy internally generated cash to drive stakeholder value." Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q2 Fiscal Year 2025 Stakeholder Letter. Fiscal Second Quarter Ended July 31, 2024 Highlights Total revenue was
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal second quarter 2025 financial results after the close of market trading on Wednesday, Sept. 4, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal second quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or v
Phreesia will work with the NAI to shape the national conversation around data privacy and promote consumer choice and transparency As part of the company's ongoing commitment to consumer data privacy, Phreesia is pleased to announce it has joined the Network Advertising Initiative (NAI), a non–profit organization and the leading self-regulatory association dedicated to responsible data collection and use for digital advertising. As a member, Phreesia will work with the NAI to promote consumer-centric privacy practices in healthcare and take a leadership role in shaping the national conversation around data privacy. "We are excited to join the NAI, an organization that shares our dedicati
Phreesia, a leader in patient intake, outreach and activation, is proud to announce that Audrey Gato, Vice President of Client Solutions, has been named to The Software Report's list of the Top 50 Women Leaders in SaaS of 2023. Honorees were chosen based on their leadership and contributions to the Software-as-a-Service industry. This is the sixth consecutive year a female leader from Phreesia has been named to the list. Previous Phreesia awardees include Allison Hoffman, General Counsel; Kristin Roberts, Vice President of Product Management; Kharen Hauck, Vice President of Marketing; Amy VanDuyn, Senior Vice President of Human Resources; and Sara DiNardo, Vice President of Client Solutio
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley cut the price target for Microchip Technology Incorporated (NASDAQ:MCHP) from $102 to $100. Morgan Stanley analyst Joseph Moore downgraded the stock from Overweight to Equal-Weight. Microchip Technology shares rose 3.9% to close at $95.98 on Wednesday. See how other analysts view this stock. Truist Securities lifted the price target for Astrana Health, Inc. (NASDAQ:ASTH) from $44 to $50. Truist Securities analyst Jailendra Singh upgraded the stock from Hold to Buy. Astrana Health sha
Keybanc analyst Scott Schoenhaus maintains Phreesia (NYSE:PHR) with a Overweight and lowers the price target from $27 to $25.
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Phreesia (NYSE:PHR) in the last three months. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.83, a high estimate of $34.00, and a low estimate of $28.00. A decline of 4.79% from the prior average price ta